All In Biotech

Drug Trial Radar · NCT07873671

A Trial of RLX-2508-102 in Healthy Volunteers

A Phase 1, Randomized, Double-blind, Placebo-Controlled, Single and Multiple-Dose and Extended Safety Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of RLX-2508 in Healthy Adult Participants

Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 101 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

101

Planned (sponsor's estimate)

Start

Nov 15, 2026

Primary completion

Jan 30, 2029

Study completion Jan 30, 2029

Sponsor

Lead sponsor
Atridia Pty Ltd.Industry
Sponsor type
Industry
First posted
Oct 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess safety, PK and immunogenicity profile of a single dose and multiple dose of RLX-2508 in healthy participants across different ethnic backgrounds.

Conditions

  • Influenza

Interventions

  • RLX-2508Drug

    Single dose RLX-2508 /placebo given subcutaneously - Dose level 1

  • RLX-2508Drug

    Single dose RLX-2508 /placebo given subcutaneously - Dose level 2

  • RLX-2508Drug

    Repeated dose of RLX-2508 /placebo given subcutaneously - Dose level 3

  • RLX-2508Drug

    Single dose of RLX-2508 /placebo given subcutaneously - Dose level 3

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Tolerability Based on Incidence and Severity of Treatment Emergent Adverse EventsTime frame: Day 360 & Day 450

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Nucleus Network Sydney

    Sydney, New South Wales, Australia

  • Nucleus Network Brisbane

    Brisbane, Queensland, Australia

  • Nucleus Network Melbourne

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.